Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study

Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study

Background: This study aimed to compare the efficacy of abiraterone acetate (AA) versus docetaxel (T) as first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer (mCRPC) patients with or without the ineligible factors of the COU-AA-302 study (presence of visceral metastase...

Full description

Bibliographic Details
Main Authors: Darren M.C. Poon, Kuen Chan, Siu H. Lee, Tim W. Chan, Henry Sze, Eric K.C. Lee, Daisy Lam, Michelle F.T. Chan
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Prostate International
Subjects:
Abiraterone Acetate
Castration-Resistant Prostate Cancer
Chemo-Naïve
Chemotherapy
Metastasis
Online Access:http://www.sciencedirect.com/science/article/pii/S2287888217300764

Internet

http://www.sciencedirect.com/science/article/pii/S2287888217300764

Similar Items